GALT
Galectin Therapeutics Inc.
Biotechnology
Market Cap$136M
5Y Perf.-30.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
GALT vs AKBA vs HALO vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
AKBA
Akebia Therapeutics, Inc.
Biotechnology
Market Cap$317M
5Y Perf.-89.9%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+168.6%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
GALT vs AKBA vs HALO vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GALT | AKBA | HALO | FOLD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $136M | $317M | $7.68B | $4.55B |
| Revenue (TTM) | $0.00 | $232M | $1.40B | $634M |
| Net Income (TTM) | $-37M | $-21M | $317M | $-27M |
| Gross Margin | — | 81.0% | 81.9% | 87.9% |
| Operating Margin | — | 2.3% | 58.4% | 5.2% |
| Forward P/E | — | — | 8.1x | 40.6x |
| Total Debt | $106M | $216M | $0.00 | $483M |
| Cash & Equiv. | $15M | $185M | $134M | $214M |
GALT vs AKBA vs HALO vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GALT
AKBA
HALO
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Galectin Therapeuti… (GALT) | 100 | 69.6 | -30.4% |
| Akebia Therapeutics… (AKBA) | 100 | 10.1 | -89.9% |
| Halozyme Therapeuti… (HALO) | 100 | 268.6 | +168.6% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GALT vs AKBA vs HALO vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Galectin Therapeutics Inc. is the stronger pick specifically for dividend income and shareholder returns. AKBA and FOLD also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
GALT
Galectin Therapeutics Inc.
The Income Pick
GALT is the #2 pick in this set and the best alternative if dividends is your priority.
- 0.1% yield; the other 3 pay no meaningful dividend
Best for: dividends
AKBA
Akebia Therapeutics, Inc.
The Growth Play
AKBA is the clearest fit if your priority is growth exposure.
- Rev growth 47.5%, EPS growth 93.7%, 3Y rev CAGR -6.9%
- 47.5% revenue growth vs GALT's -59.9%
Best for: growth exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.56
- 5.7% 10Y total return vs FOLD's 119.2%
- Beta 0.56, current ratio 4.66x
- Lower P/E (8.1x vs 40.6x)
Best for: income & stability and long-term compounding
FOLD
Amicus Therapeutics, Inc.
The Defensive Pick
FOLD is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.63, current ratio 2.84x
- +137.9% vs AKBA's -52.0%
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AKBA | 47.5% revenue growth vs GALT's -59.9% |
| Value | HALO | Lower P/E (8.1x vs 40.6x) |
| Quality / Margins | HALO | 22.7% margin vs GALT's -29.7% |
| Stability / Safety | HALO | Beta 0.56 vs AKBA's 1.14 |
| Dividends | GALT | 0.1% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs AKBA's -52.0% |
| Efficiency (ROA) | HALO | 12.5% ROA vs GALT's -290.0% |
GALT vs AKBA vs HALO vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
GALT vs AKBA vs HALO vs FOLD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGFOLD
Who Leads Where
HALO leads in 2 of 6 categories
AKBA leads 1 • GALT leads 0 • FOLD leads 0 • 2 tied
Explore the data ↓FOLDAmicus Therapeutics, …
0leads
GALTGalectin Therapeutics…
0leads
AKBAAkebia Therapeutics, …
1leads
HALOHalozyme Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs AKBAvs GALTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO4/6
Valuation MetricsMultiples, price ratios, and targets
AKBA3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO and GALT operate at a comparable scale, with $1.4B and $0 in trailing revenue. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to AKBA's -8.8%. On growth, HALO holds the edge at +51.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GALTGalectin Therapeu… | AKBAAkebia Therapeuti… | HALOHalozyme Therapeu… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $232M | $1.4B | $634M |
| EBITDAEarnings before interest/tax | -$31M | $6M | $945M | $40M |
| Net IncomeAfter-tax profit | -$37M | -$21M | $317M | -$27M |
| Free Cash FlowCash after capex | -$31M | $60M | $645M | $30M |
| Gross MarginGross profit ÷ Revenue | — | +81.0% | +81.9% | +87.9% |
| Operating MarginEBIT ÷ Revenue | — | +2.3% | +58.4% | +5.2% |
| Net MarginNet income ÷ Revenue | — | -8.8% | +22.7% | -4.3% |
| FCF MarginFCF ÷ Revenue | — | +25.8% | +46.2% | +4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -6.6% | +51.6% | +23.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.8% | -2.2% | -2.1% | -89.0% |
HALO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
AKBA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, HALO's 8.3x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | GALTGalectin Therapeu… | AKBAAkebia Therapeuti… | HALOHalozyme Therapeu… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $136M | $317M | $7.7B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $227M | $348M | $7.5B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.78x | -56.73x | 25.46x | -164.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 8.09x | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.11x | — |
| EV / EBITDAEnterprise value multiple | — | 14.05x | 8.34x | 114.88x |
| Price / SalesMarket cap ÷ Revenue | — | 1.34x | 5.50x | 7.17x |
| Price / BookPrice ÷ Book value/share | — | 9.31x | 165.47x | 16.29x |
| Price / FCFMarket cap ÷ FCF | — | 4.66x | 11.91x | 152.43x |
AKBA leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-63 for AKBA. FOLD carries lower financial leverage with a 1.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to AKBA's 6.63x. On the Piotroski fundamental quality scale (0–9), AKBA scores 5/9 vs GALT's 1/9, reflecting solid financial health.
| Metric | GALTGalectin Therapeu… | AKBAAkebia Therapeuti… | HALOHalozyme Therapeu… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -62.7% | +6.5% | -12.0% |
| ROA (TTM)Return on assets | -2.9% | -5.7% | +12.5% | -3.2% |
| ROICReturn on invested capital | — | +23.2% | +73.4% | +5.3% |
| ROCEReturn on capital employed | — | +13.3% | +38.2% | +5.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 | 5 | 4 |
| Debt / EquityFinancial leverage | — | 6.63x | — | 1.76x |
| Net DebtTotal debt minus cash | $91M | $31M | -$134M | $269M |
| Cash & Equiv.Liquid assets | $15M | $185M | $134M | $214M |
| Total DebtShort + long-term debt | $106M | $216M | $0 | $483M |
| Interest CoverageEBIT ÷ Interest expense | -4.24x | 0.56x | 46.08x | 1.00x |
HALO leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — HALO and FOLD each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOLD five years ago would be worth $14,862 today (with dividends reinvested), compared to $3,782 for AKBA. Over the past 12 months, FOLD leads with a +137.9% total return vs AKBA's -52.0%. The 3-year compound annual growth rate (CAGR) favors HALO at 29.1% vs AKBA's 3.6% — a key indicator of consistent wealth creation.
| Metric | GALTGalectin Therapeu… | AKBAAkebia Therapeuti… | HALOHalozyme Therapeu… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -47.9% | -23.9% | -7.3% | +1.5% |
| 1-Year ReturnPast 12 months | +34.4% | -52.0% | -7.1% | +137.9% |
| 3-Year ReturnCumulative with dividends | +12.2% | +11.3% | +115.3% | +19.0% |
| 5-Year ReturnCumulative with dividends | -47.2% | -62.2% | +37.0% | +48.6% |
| 10-Year ReturnCumulative with dividends | +67.4% | -85.7% | +570.7% | +119.2% |
| CAGR (3Y)Annualised 3-year return | +3.9% | +3.6% | +29.1% | +6.0% |
Evenly matched — HALO and FOLD each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — HALO and FOLD each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than AKBA's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs AKBA's 28.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GALTGalectin Therapeu… | AKBAAkebia Therapeuti… | HALOHalozyme Therapeu… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.14x | 0.56x | 0.63x |
| 52-Week HighHighest price in past year | $7.13 | $4.08 | $82.22 | $14.50 |
| 52-Week LowLowest price in past year | $1.21 | $1.13 | $47.50 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +29.6% | +28.9% | +79.3% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 55.9 | 52.4 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 347K | 2.8M | 1.4M | 3.0M |
Evenly matched — HALO and FOLD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GALT as "Buy", AKBA as "Buy", HALO as "Buy", FOLD as "Buy". Consensus price targets imply 421.3% upside for GALT (target: $11) vs 0.1% for FOLD (target: $15).
| Metric | GALTGalectin Therapeu… | AKBAAkebia Therapeuti… | HALOHalozyme Therapeu… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $11.00 | $4.00 | $78.33 | $14.50 |
| # AnalystsCovering analysts | 11 | 11 | 27 | 24 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | $0.00 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.5% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AKBA leads in 1 (Valuation Metrics). 2 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 2 of 6 categories
Loading custom metrics...
GALT vs AKBA vs HALO vs FOLD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GALT or AKBA or HALO or FOLD a better buy right now?
For growth investors, Akebia Therapeutics, Inc.
(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Galectin Therapeutics Inc. (GALT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GALT or AKBA or HALO or FOLD?
On forward P/E, Halozyme Therapeutics, Inc.
is actually cheaper at 8. 1x.
03Which is the better long-term investment — GALT or AKBA or HALO or FOLD?
Over the past 5 years, Amicus Therapeutics, Inc.
(FOLD) delivered a total return of +48. 6%, compared to -62. 2% for Akebia Therapeutics, Inc. (AKBA). Over 10 years, the gap is even starker: HALO returned +570. 7% versus AKBA's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GALT or AKBA or HALO or FOLD?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Akebia Therapeutics, Inc. 's 1. 14β — meaning AKBA is approximately 104% more volatile than HALO relative to the S&P 500. On balance sheet safety, Amicus Therapeutics, Inc. (FOLD) carries a lower debt/equity ratio of 176% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GALT or AKBA or HALO or FOLD?
By revenue growth (latest reported year), Akebia Therapeutics, Inc.
(AKBA) is pulling ahead at 47. 5% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GALT or AKBA or HALO or FOLD?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -4. 3% for Amicus Therapeutics, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for GALT. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GALT or AKBA or HALO or FOLD more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 1x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 32. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GALT: 421. 3% to $11. 00.
08Which pays a better dividend — GALT or AKBA or HALO or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is GALT or AKBA or HALO or FOLD better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, AKBA: -85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GALT and AKBA and HALO and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GALT is a small-cap quality compounder stock; AKBA is a small-cap high-growth stock; HALO is a small-cap high-growth stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.